NHS has begun offering Mounjaro to individuals in specific group
NHS has begun offering Mounjaro to individuals in specific group. This article explains how the treatment works, who may qualify through the NHS, and what kind of medical support accompanies its use.
What Is Mounjaro and How Does It Work?
Mounjaro is a dual-hormone agonist that mimics the effects of GLP-1 and GIP, two natural hormones involved in hunger regulation and metabolic function.
In clinical studies, Mounjaro has shown average weight reduction of 20–23% over 72 weeks when combined with appropriate lifestyle interventions. It is administered via a prefilled injection device (KwikPen®), designed for weekly use.
Reported benefits include:
• Reduced appetite and food cravings
• Slower digestion to promote fullness
• Improved insulin response
• Decreased fat accumulation
NHS Access: Who May Be Eligible?
According to guidance published by NICE in December 2024, Mounjaro may be considered under the NHS for adults who:
• Have a BMI of 35 or above
• Also have at least one health condition related to weight, such as:
• Type 2 diabetes
• High blood pressure
• Osteoarthritis
• High cholesterol
• Sleep apnea
For certain ethnic backgrounds—including South Asian, Black African, Middle Eastern, and Chinese communities—the BMI threshold may be adjusted to 32.5, reflecting increased health risks at lower BMI levels.
Access follows a phased approach:
• Since March 2025, Mounjaro has been available through NHS specialist weight management clinics, which support individuals with severe obesity. These services require a referral from a GP.
• From June 2025, some patients may be eligible to receive Mounjaro directly from their local GP, but only if they fall into high-risk categories and meet specific medical criteria. This rollout depends on the availability of structured support programs.
All NHS prescriptions must be accompanied by ongoing care, including:
• Nutritional counselling
• Behavioural support
• Regular treatment reviews and dose monitoring
A Department of Health and Social Care spokesperson said making the drugs available to those who need them most would help "tackling the obesity crisis head-on, and these weight loss drugs could greatly benefit those who really need them, when they are needed."
Access Through Private Providers
Individuals who do not meet NHS criteria may choose to obtain Mounjaro through licensed private pharmacies or clinics. Eligibility typically requires:
• BMI ≥30
• Or ≥27 with additional weight-related conditions such as prediabetes or PCOS
💷 Estimated pricing:
• Starter pack (2.5 mg or 5 mg, 4 weeks): £129–£179
• Maintenance doses (up to 15 mg): £179–£250 per month
Some platforms offer consultations, home delivery, and follow-up guidance. Prices may vary between providers.
Reported Patient Experiences
“After changing medications, I experienced more consistent appetite control and improved energy levels.” — 42-year-old user from Buckinghamshire
“Over six months, I lost 18% of my body weight with regular reviews and ongoing support.” — Male patient, age 54
"Good ! I've been paying privately for mounjaro for the past 5 months and my life has completely changed." - Male patient, age 71
Considerations and Side Effects
Common side effects may include: nausea, digestive discomfort, mild bloating.
These typically improve over time and can be minimized by gradual dose adjustment under clinical supervision.
Conclusion
Mounjaro is one of several new medical options for managing obesity in the UK. It offers a treatment path supported by clinical evidence and professional oversight.